Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer Kadoaki Ohashi, MD, Kastuyuki Kiura, MD, PhD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer W Jeffrey Petty, MD, Sommer N.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Triple Combination Chemotherapy with Cisplatin, Docetaxel, and Irinotecan for Advanced Non-small Cell Lung Cancer: A Phase I/II Trial Katsuyuki Kiura,

Synchronous Pulmonary MALT Lymphoma and Pulmonary Adenocarcinoma after Metachronous Gastric MALT Lymphoma and Gastric Adenocarcinoma Eiki Ichihara, MD,

Lung Cancer with Localized Ground-Glass Attenuation Represents Early-Stage Adenocarcinoma in Nonsmokers Nobuhiko Seki, MD, Shigeki Sawada, MD, Masao.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer Yoichi Nakamura, MD, PhD, Kazumi Sano, PhD, Hiroshi.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Erratum Journal of Thoracic Oncology

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk.

Visceral Pleural Invasion Classification in Non-small Cell Lung Cancer

Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

A Retrospective Analysis of Clinical Outcomes of Patients Older Than or Equal to 80 Years with Small Cell Lung Cancer Toshiyuki Noguchi, MD, Hideaki.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Presentation of Garcin Syndrome due to Lung Cancer

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Palliative Thoracic Radiotherapy in Locally Advanced Non-small Cell Lung Cancer: Can Quality-Of-Life Assessments Help in Selection of Patients for Short-

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Visceral Pleural Invasion Classification in Non–Small-Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer:

Presentation transcript:

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer Shoichi Kuyama, MD, Katsuyuki Hotta, MD, PhD, Masahiro Tabata, MD, PhD, Yoshihiko Segawa, MD, PhD, Yoshiro Fujiwara, MD, Nagio Takigawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Hiroshi Ueoka, MD, PhD, Kenji Eguchi, MD, PhD, Mitsune Tanimoto, MD, PhD Journal of Thoracic Oncology Volume 3, Issue 5, Pages 477-482 (May 2008) DOI: 10.1097/JTO.0b013e31816e2ea3 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Association between the HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assay results. The FISH results were expressed as the ratio of HER2 to chromosome 17 copy number in each patient. The IHC results were divided into two categories according to the HercepTest kit scoring guidelines: negative (score 0 to 1+) and positive (score 2+ to 3+). Journal of Thoracic Oncology 2008 3, 477-482DOI: (10.1097/JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Survival curves stratified by HER2-fluorescence in situ hybridization (FISH) results. Bold and nonbold lines represent patients with positive and negative FISH results, respectively. A, Overall survival Curves (5-year overall survival rate and median survival time of patients with HER2-FISH positive and negative tumors of 22.7% and 40.9%, respectively, and 15.5 months and 29.7 months, respectively; log-rank test; p = 0.1352). B, Progression-Free survival Curves (median progression-free survival times of 10.0 months and 14.1 month in those with the positive and negative HER2-FISH results, respectively, log-rank test; p = 0.0871). Journal of Thoracic Oncology 2008 3, 477-482DOI: (10.1097/JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Survival curves stratified by HER2-FISH results. Bold and nonbold lines represent patients with HER2-protein positive (score 2+ to 3+) and negative (score 0 to 1+) tumors, respectively. A, Overall survival Curves (5-year overall survival rate and median survival time of patients with HER2-FISH positive and negative tumors of 39.1% and 31.1%, respectively, and 28.3 months and 23.6 months, respectively; log-rank test; p = 0.4986). B, Progression-Free survival Curves (median progression-free survival times of 14.1 month and 10.6 months in those with the positive and negative HER2-FISH results, respectively, log-rank test; p = 0.8843). Journal of Thoracic Oncology 2008 3, 477-482DOI: (10.1097/JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions